Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 10.7% Higher – Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was up 10.7% on Wednesday . The company traded as high as $12.05 and last traded at $11.78. Approximately 29,323,578 shares changed hands during trading, an increase of 21% from the average daily volume of 24,262,922 shares. The stock had previously closed at $10.64.

Analyst Ratings Changes

Several research firms recently issued reports on RXRX. KeyCorp dropped their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The business has a 50 day simple moving average of $7.52 and a 200-day simple moving average of $7.00. The firm has a market cap of $3.63 billion, a price-to-earnings ratio of -6.07 and a beta of 0.86.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Ensign Peak Advisors Inc grew its position in Recursion Pharmaceuticals by 0.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock worth $2,774,000 after purchasing an additional 1,300 shares in the last quarter. Farther Finance Advisors LLC grew its position in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after buying an additional 1,353 shares during the period. Axxcess Wealth Management LLC increased its holdings in Recursion Pharmaceuticals by 4.3% during the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after buying an additional 1,795 shares during the last quarter. Summit Investment Advisors Inc. raised its position in Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock worth $176,000 after acquiring an additional 1,875 shares during the period. Finally, Wedmont Private Capital boosted its stake in Recursion Pharmaceuticals by 10.6% in the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock valued at $144,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.